StockData

GeoVax Labs vs MediciNova

GOVX and MNOV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GOVX and MNOV compare

MediciNova is the larger company, worth 4.5 times as much as GeoVax Labs ($66.0M against $14.8M).

MediciNova scores higher on the StockData Score (7 against 6 for GeoVax Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGOVXMNOV
Size and price
Market cap$14.8M$66.0M
Share price$2.01$1.34
Change, 1 year−99.3%−13.5%
Change, 5 years−100.0%−58.4%
Beta (5Y)–−0.00
Employees196
StockData Score
Total score67 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S–71.7×
P/B8.4×1.8× (better)
FCF yield−124%−13.8% (better)
Growth
Revenue growth (TTM)−100%–
Revenue growth, 5Y average6.4%–
Profitability
Operating margin–−1287%
Net margin–−1168%
FCF margin–−991%
Return on equity−892%−25.6% (better)
Return on invested capital–−76.6%
Financial health
Debt / equity0.000.00
Current ratio1.548.75 (better)
Altman Z-score−59.53−3.11 (better)
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions6.7%10.5%
Held by insiders2.7%12.8%
Insider net buying, 12 months$0 (better)−$1.7M
Short interest, % of float2.5%0.66%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.